Research ArticleArticle
Open Access
Development and Validation of a Self-Administered Questionnaire Measuring Essential Knowledge in Patients With Axial Spondyloarthritis
Catherine Beauvais, Bruno Pereira, Thao Pham, Christelle Sordet, Pascal Claudepierre, Françoise Fayet, Daniel Wendling, Félicie Costantino, Laurence Carton, Laurent Grange, Martin Soubrier, Nathalie Legoupil, Aleth Perdriger, Isabel Tavares, Emmanuelle Dernis, Laure Gossec and Malory Rodère
The Journal of Rheumatology July 2022, jrheum.211314; DOI: https://doi.org/10.3899/jrheum.211314
Catherine Beauvais
The study was supported by an institutional grant from the University Hospital of Clermont-Ferrand (Centre Hospitalier Universitaire Gabriel-Montpied, Clermont-Ferrand, France; reference AOI RODERE 2016). C. Beauvais, MD, Service de Rhumatologie Centre Hospitalier Universitaire Saint Antoine, Sorbonne Université, AP-HP, Paris; 2. Pereira, PhD, Département de Biostatistique Centre Hospitalier Universitaire Gabriel-Montpied, Clermont-Ferrand; T. Pham, MD, PhD, Service de Rhumatologie, Centre Hospitalier Universitaire Sainte Marguerite, Université Aix Marseille, Marseille; C. Sordet, MD, PhD, Service de Rhumatologie, Hôpitaux Universitaires Strasbourg, Strasbourg; P. Claudepierre, MD, PhD, Service de Rhumatologie, Centre Hospitalier Universitaire Henri Mondor, AP-HP, Université Créteil, Paris; F. Fayet, BSc, M. Soubrier, MD, PhD, M. Rodère, BSc, Service de Rhumatologie, Centre Hospitalier Universitaire Gabriel-Montpied, Clermont-Ferrand; D. Wendling, MD, PhD, Service de Rhumatologie, Centre Hospitalier Régional Universitaire de Besançon, and EA 4266 EPILAB, Université Bourgogne Franche-Comté, Besançon; F. Costantino, MD, PhD, Service de Rhumatologie, Hôpital Universitaire Ambroise Paré, AP-HP, Université Paris Saclay, Boulogne-Billancourt; L. Carton, Association AFLAR (Association Française de Lutte Anti-Rhumatismale), Paris; L. Grange, MD, PhD, Service de Rhumatologie, Centre Hospitalier Universitaire Grenoble Alpes, Echirolles; N. Legoupil, MD, Service de Rhumatologie, Centre Hospitalier Universitaire Cochin, AP-HP, Paris; A. Perdriger, MD, PhD, Service de Rhumatologie, Centre Hospitalier Universitaire, Rennes; I. Tavares, Service de Rééducation, Hôpital Universitaire Montpellier, Montpellier; E. Dernis, MD, MSc, Service de Rhumatologie, Hôpital Le Mans, Le Mans; L. Gossec, Sorbonne Université, Institut Pierre Louis d'Epidémiologie et de Santé Publique, INSERM, and Service de Rhumatologie, Centre Hospitalier Universitaire Pitié Salpétrière, Sorbonne Université AP-HP, Paris France. CB has received research grants from BMS, Fresenius Kabi, Eli Lilly, and Mylan; advisory board fees from Novartis and Sandoz; and speaker fees from BMS, AbbVie, MSD, Mylan, Pfizer, Roche, Sanofi, and UCB. TP has received speaker and consulting fees from AbbVie, Amgen, Biogen, BMS, Celgene, Fresenius Kabi, Janssen, Eli Lilly, MSD, Nordic Pharma, Novartis, Pfizer, Sandoz, Sanofi, and UCB. CS has received consulting fees from AbbVie, UCB, Eli Lilly, Nordic Pharma, GSK, Roche Chugaï, and BMS. DW has received speaker fees from AbbVie, BMS, MSD, Pfizer, Chugaï, Nordic Pharma, UCB, Novartis, Eli Lilly, Amgen, Grunenthal, and Galapagos; advisory board fees from Novartis, Janssen, AbbVie, and Amgen; and support for attending meetings from MSD, Galapagos, Chugaï, UCB, Mylan, and Fresenius Kabi. FC has received consulting and/or speaker fees from Eli Lilly, Novartis, and UCB. LG has received research grants from Amgen, Galapagos, Janssen, Eli Lilly, Pfizer, Sandoz, Sanofi; and consulting fees from AbbVie, Amgen, BMS, Biogen, Celgene, Galapagos, Gilead, Janssen, Eli Lilly, Novartis, Pfizer, Samsung Bioepis, Sanofi-Aventis, and UCB. The remaining authors declare no conflicts of interest. Address correspondence to Dr. C. Beauvais, Service de Rhumatologie Centre Hospitalier Universitaire Saint Antoine, Sorbonne Université, AP-HP, 184 rue du Faubourg Saint Antoine, 75012 Paris, France. Email: catherine.beauvais@aphp.fr. Accepted for publication July 6, 2022.
Bruno Pereira
The study was supported by an institutional grant from the University Hospital of Clermont-Ferrand (Centre Hospitalier Universitaire Gabriel-Montpied, Clermont-Ferrand, France; reference AOI RODERE 2016). C. Beauvais, MD, Service de Rhumatologie Centre Hospitalier Universitaire Saint Antoine, Sorbonne Université, AP-HP, Paris; 2. Pereira, PhD, Département de Biostatistique Centre Hospitalier Universitaire Gabriel-Montpied, Clermont-Ferrand; T. Pham, MD, PhD, Service de Rhumatologie, Centre Hospitalier Universitaire Sainte Marguerite, Université Aix Marseille, Marseille; C. Sordet, MD, PhD, Service de Rhumatologie, Hôpitaux Universitaires Strasbourg, Strasbourg; P. Claudepierre, MD, PhD, Service de Rhumatologie, Centre Hospitalier Universitaire Henri Mondor, AP-HP, Université Créteil, Paris; F. Fayet, BSc, M. Soubrier, MD, PhD, M. Rodère, BSc, Service de Rhumatologie, Centre Hospitalier Universitaire Gabriel-Montpied, Clermont-Ferrand; D. Wendling, MD, PhD, Service de Rhumatologie, Centre Hospitalier Régional Universitaire de Besançon, and EA 4266 EPILAB, Université Bourgogne Franche-Comté, Besançon; F. Costantino, MD, PhD, Service de Rhumatologie, Hôpital Universitaire Ambroise Paré, AP-HP, Université Paris Saclay, Boulogne-Billancourt; L. Carton, Association AFLAR (Association Française de Lutte Anti-Rhumatismale), Paris; L. Grange, MD, PhD, Service de Rhumatologie, Centre Hospitalier Universitaire Grenoble Alpes, Echirolles; N. Legoupil, MD, Service de Rhumatologie, Centre Hospitalier Universitaire Cochin, AP-HP, Paris; A. Perdriger, MD, PhD, Service de Rhumatologie, Centre Hospitalier Universitaire, Rennes; I. Tavares, Service de Rééducation, Hôpital Universitaire Montpellier, Montpellier; E. Dernis, MD, MSc, Service de Rhumatologie, Hôpital Le Mans, Le Mans; L. Gossec, Sorbonne Université, Institut Pierre Louis d'Epidémiologie et de Santé Publique, INSERM, and Service de Rhumatologie, Centre Hospitalier Universitaire Pitié Salpétrière, Sorbonne Université AP-HP, Paris France. CB has received research grants from BMS, Fresenius Kabi, Eli Lilly, and Mylan; advisory board fees from Novartis and Sandoz; and speaker fees from BMS, AbbVie, MSD, Mylan, Pfizer, Roche, Sanofi, and UCB. TP has received speaker and consulting fees from AbbVie, Amgen, Biogen, BMS, Celgene, Fresenius Kabi, Janssen, Eli Lilly, MSD, Nordic Pharma, Novartis, Pfizer, Sandoz, Sanofi, and UCB. CS has received consulting fees from AbbVie, UCB, Eli Lilly, Nordic Pharma, GSK, Roche Chugaï, and BMS. DW has received speaker fees from AbbVie, BMS, MSD, Pfizer, Chugaï, Nordic Pharma, UCB, Novartis, Eli Lilly, Amgen, Grunenthal, and Galapagos; advisory board fees from Novartis, Janssen, AbbVie, and Amgen; and support for attending meetings from MSD, Galapagos, Chugaï, UCB, Mylan, and Fresenius Kabi. FC has received consulting and/or speaker fees from Eli Lilly, Novartis, and UCB. LG has received research grants from Amgen, Galapagos, Janssen, Eli Lilly, Pfizer, Sandoz, Sanofi; and consulting fees from AbbVie, Amgen, BMS, Biogen, Celgene, Galapagos, Gilead, Janssen, Eli Lilly, Novartis, Pfizer, Samsung Bioepis, Sanofi-Aventis, and UCB. The remaining authors declare no conflicts of interest. Address correspondence to Dr. C. Beauvais, Service de Rhumatologie Centre Hospitalier Universitaire Saint Antoine, Sorbonne Université, AP-HP, 184 rue du Faubourg Saint Antoine, 75012 Paris, France. Email: catherine.beauvais@aphp.fr. Accepted for publication July 6, 2022.
Thao Pham
The study was supported by an institutional grant from the University Hospital of Clermont-Ferrand (Centre Hospitalier Universitaire Gabriel-Montpied, Clermont-Ferrand, France; reference AOI RODERE 2016). C. Beauvais, MD, Service de Rhumatologie Centre Hospitalier Universitaire Saint Antoine, Sorbonne Université, AP-HP, Paris; 2. Pereira, PhD, Département de Biostatistique Centre Hospitalier Universitaire Gabriel-Montpied, Clermont-Ferrand; T. Pham, MD, PhD, Service de Rhumatologie, Centre Hospitalier Universitaire Sainte Marguerite, Université Aix Marseille, Marseille; C. Sordet, MD, PhD, Service de Rhumatologie, Hôpitaux Universitaires Strasbourg, Strasbourg; P. Claudepierre, MD, PhD, Service de Rhumatologie, Centre Hospitalier Universitaire Henri Mondor, AP-HP, Université Créteil, Paris; F. Fayet, BSc, M. Soubrier, MD, PhD, M. Rodère, BSc, Service de Rhumatologie, Centre Hospitalier Universitaire Gabriel-Montpied, Clermont-Ferrand; D. Wendling, MD, PhD, Service de Rhumatologie, Centre Hospitalier Régional Universitaire de Besançon, and EA 4266 EPILAB, Université Bourgogne Franche-Comté, Besançon; F. Costantino, MD, PhD, Service de Rhumatologie, Hôpital Universitaire Ambroise Paré, AP-HP, Université Paris Saclay, Boulogne-Billancourt; L. Carton, Association AFLAR (Association Française de Lutte Anti-Rhumatismale), Paris; L. Grange, MD, PhD, Service de Rhumatologie, Centre Hospitalier Universitaire Grenoble Alpes, Echirolles; N. Legoupil, MD, Service de Rhumatologie, Centre Hospitalier Universitaire Cochin, AP-HP, Paris; A. Perdriger, MD, PhD, Service de Rhumatologie, Centre Hospitalier Universitaire, Rennes; I. Tavares, Service de Rééducation, Hôpital Universitaire Montpellier, Montpellier; E. Dernis, MD, MSc, Service de Rhumatologie, Hôpital Le Mans, Le Mans; L. Gossec, Sorbonne Université, Institut Pierre Louis d'Epidémiologie et de Santé Publique, INSERM, and Service de Rhumatologie, Centre Hospitalier Universitaire Pitié Salpétrière, Sorbonne Université AP-HP, Paris France. CB has received research grants from BMS, Fresenius Kabi, Eli Lilly, and Mylan; advisory board fees from Novartis and Sandoz; and speaker fees from BMS, AbbVie, MSD, Mylan, Pfizer, Roche, Sanofi, and UCB. TP has received speaker and consulting fees from AbbVie, Amgen, Biogen, BMS, Celgene, Fresenius Kabi, Janssen, Eli Lilly, MSD, Nordic Pharma, Novartis, Pfizer, Sandoz, Sanofi, and UCB. CS has received consulting fees from AbbVie, UCB, Eli Lilly, Nordic Pharma, GSK, Roche Chugaï, and BMS. DW has received speaker fees from AbbVie, BMS, MSD, Pfizer, Chugaï, Nordic Pharma, UCB, Novartis, Eli Lilly, Amgen, Grunenthal, and Galapagos; advisory board fees from Novartis, Janssen, AbbVie, and Amgen; and support for attending meetings from MSD, Galapagos, Chugaï, UCB, Mylan, and Fresenius Kabi. FC has received consulting and/or speaker fees from Eli Lilly, Novartis, and UCB. LG has received research grants from Amgen, Galapagos, Janssen, Eli Lilly, Pfizer, Sandoz, Sanofi; and consulting fees from AbbVie, Amgen, BMS, Biogen, Celgene, Galapagos, Gilead, Janssen, Eli Lilly, Novartis, Pfizer, Samsung Bioepis, Sanofi-Aventis, and UCB. The remaining authors declare no conflicts of interest. Address correspondence to Dr. C. Beauvais, Service de Rhumatologie Centre Hospitalier Universitaire Saint Antoine, Sorbonne Université, AP-HP, 184 rue du Faubourg Saint Antoine, 75012 Paris, France. Email: catherine.beauvais@aphp.fr. Accepted for publication July 6, 2022.
Christelle Sordet
The study was supported by an institutional grant from the University Hospital of Clermont-Ferrand (Centre Hospitalier Universitaire Gabriel-Montpied, Clermont-Ferrand, France; reference AOI RODERE 2016). C. Beauvais, MD, Service de Rhumatologie Centre Hospitalier Universitaire Saint Antoine, Sorbonne Université, AP-HP, Paris; 2. Pereira, PhD, Département de Biostatistique Centre Hospitalier Universitaire Gabriel-Montpied, Clermont-Ferrand; T. Pham, MD, PhD, Service de Rhumatologie, Centre Hospitalier Universitaire Sainte Marguerite, Université Aix Marseille, Marseille; C. Sordet, MD, PhD, Service de Rhumatologie, Hôpitaux Universitaires Strasbourg, Strasbourg; P. Claudepierre, MD, PhD, Service de Rhumatologie, Centre Hospitalier Universitaire Henri Mondor, AP-HP, Université Créteil, Paris; F. Fayet, BSc, M. Soubrier, MD, PhD, M. Rodère, BSc, Service de Rhumatologie, Centre Hospitalier Universitaire Gabriel-Montpied, Clermont-Ferrand; D. Wendling, MD, PhD, Service de Rhumatologie, Centre Hospitalier Régional Universitaire de Besançon, and EA 4266 EPILAB, Université Bourgogne Franche-Comté, Besançon; F. Costantino, MD, PhD, Service de Rhumatologie, Hôpital Universitaire Ambroise Paré, AP-HP, Université Paris Saclay, Boulogne-Billancourt; L. Carton, Association AFLAR (Association Française de Lutte Anti-Rhumatismale), Paris; L. Grange, MD, PhD, Service de Rhumatologie, Centre Hospitalier Universitaire Grenoble Alpes, Echirolles; N. Legoupil, MD, Service de Rhumatologie, Centre Hospitalier Universitaire Cochin, AP-HP, Paris; A. Perdriger, MD, PhD, Service de Rhumatologie, Centre Hospitalier Universitaire, Rennes; I. Tavares, Service de Rééducation, Hôpital Universitaire Montpellier, Montpellier; E. Dernis, MD, MSc, Service de Rhumatologie, Hôpital Le Mans, Le Mans; L. Gossec, Sorbonne Université, Institut Pierre Louis d'Epidémiologie et de Santé Publique, INSERM, and Service de Rhumatologie, Centre Hospitalier Universitaire Pitié Salpétrière, Sorbonne Université AP-HP, Paris France. CB has received research grants from BMS, Fresenius Kabi, Eli Lilly, and Mylan; advisory board fees from Novartis and Sandoz; and speaker fees from BMS, AbbVie, MSD, Mylan, Pfizer, Roche, Sanofi, and UCB. TP has received speaker and consulting fees from AbbVie, Amgen, Biogen, BMS, Celgene, Fresenius Kabi, Janssen, Eli Lilly, MSD, Nordic Pharma, Novartis, Pfizer, Sandoz, Sanofi, and UCB. CS has received consulting fees from AbbVie, UCB, Eli Lilly, Nordic Pharma, GSK, Roche Chugaï, and BMS. DW has received speaker fees from AbbVie, BMS, MSD, Pfizer, Chugaï, Nordic Pharma, UCB, Novartis, Eli Lilly, Amgen, Grunenthal, and Galapagos; advisory board fees from Novartis, Janssen, AbbVie, and Amgen; and support for attending meetings from MSD, Galapagos, Chugaï, UCB, Mylan, and Fresenius Kabi. FC has received consulting and/or speaker fees from Eli Lilly, Novartis, and UCB. LG has received research grants from Amgen, Galapagos, Janssen, Eli Lilly, Pfizer, Sandoz, Sanofi; and consulting fees from AbbVie, Amgen, BMS, Biogen, Celgene, Galapagos, Gilead, Janssen, Eli Lilly, Novartis, Pfizer, Samsung Bioepis, Sanofi-Aventis, and UCB. The remaining authors declare no conflicts of interest. Address correspondence to Dr. C. Beauvais, Service de Rhumatologie Centre Hospitalier Universitaire Saint Antoine, Sorbonne Université, AP-HP, 184 rue du Faubourg Saint Antoine, 75012 Paris, France. Email: catherine.beauvais@aphp.fr. Accepted for publication July 6, 2022.
Pascal Claudepierre
The study was supported by an institutional grant from the University Hospital of Clermont-Ferrand (Centre Hospitalier Universitaire Gabriel-Montpied, Clermont-Ferrand, France; reference AOI RODERE 2016). C. Beauvais, MD, Service de Rhumatologie Centre Hospitalier Universitaire Saint Antoine, Sorbonne Université, AP-HP, Paris; 2. Pereira, PhD, Département de Biostatistique Centre Hospitalier Universitaire Gabriel-Montpied, Clermont-Ferrand; T. Pham, MD, PhD, Service de Rhumatologie, Centre Hospitalier Universitaire Sainte Marguerite, Université Aix Marseille, Marseille; C. Sordet, MD, PhD, Service de Rhumatologie, Hôpitaux Universitaires Strasbourg, Strasbourg; P. Claudepierre, MD, PhD, Service de Rhumatologie, Centre Hospitalier Universitaire Henri Mondor, AP-HP, Université Créteil, Paris; F. Fayet, BSc, M. Soubrier, MD, PhD, M. Rodère, BSc, Service de Rhumatologie, Centre Hospitalier Universitaire Gabriel-Montpied, Clermont-Ferrand; D. Wendling, MD, PhD, Service de Rhumatologie, Centre Hospitalier Régional Universitaire de Besançon, and EA 4266 EPILAB, Université Bourgogne Franche-Comté, Besançon; F. Costantino, MD, PhD, Service de Rhumatologie, Hôpital Universitaire Ambroise Paré, AP-HP, Université Paris Saclay, Boulogne-Billancourt; L. Carton, Association AFLAR (Association Française de Lutte Anti-Rhumatismale), Paris; L. Grange, MD, PhD, Service de Rhumatologie, Centre Hospitalier Universitaire Grenoble Alpes, Echirolles; N. Legoupil, MD, Service de Rhumatologie, Centre Hospitalier Universitaire Cochin, AP-HP, Paris; A. Perdriger, MD, PhD, Service de Rhumatologie, Centre Hospitalier Universitaire, Rennes; I. Tavares, Service de Rééducation, Hôpital Universitaire Montpellier, Montpellier; E. Dernis, MD, MSc, Service de Rhumatologie, Hôpital Le Mans, Le Mans; L. Gossec, Sorbonne Université, Institut Pierre Louis d'Epidémiologie et de Santé Publique, INSERM, and Service de Rhumatologie, Centre Hospitalier Universitaire Pitié Salpétrière, Sorbonne Université AP-HP, Paris France. CB has received research grants from BMS, Fresenius Kabi, Eli Lilly, and Mylan; advisory board fees from Novartis and Sandoz; and speaker fees from BMS, AbbVie, MSD, Mylan, Pfizer, Roche, Sanofi, and UCB. TP has received speaker and consulting fees from AbbVie, Amgen, Biogen, BMS, Celgene, Fresenius Kabi, Janssen, Eli Lilly, MSD, Nordic Pharma, Novartis, Pfizer, Sandoz, Sanofi, and UCB. CS has received consulting fees from AbbVie, UCB, Eli Lilly, Nordic Pharma, GSK, Roche Chugaï, and BMS. DW has received speaker fees from AbbVie, BMS, MSD, Pfizer, Chugaï, Nordic Pharma, UCB, Novartis, Eli Lilly, Amgen, Grunenthal, and Galapagos; advisory board fees from Novartis, Janssen, AbbVie, and Amgen; and support for attending meetings from MSD, Galapagos, Chugaï, UCB, Mylan, and Fresenius Kabi. FC has received consulting and/or speaker fees from Eli Lilly, Novartis, and UCB. LG has received research grants from Amgen, Galapagos, Janssen, Eli Lilly, Pfizer, Sandoz, Sanofi; and consulting fees from AbbVie, Amgen, BMS, Biogen, Celgene, Galapagos, Gilead, Janssen, Eli Lilly, Novartis, Pfizer, Samsung Bioepis, Sanofi-Aventis, and UCB. The remaining authors declare no conflicts of interest. Address correspondence to Dr. C. Beauvais, Service de Rhumatologie Centre Hospitalier Universitaire Saint Antoine, Sorbonne Université, AP-HP, 184 rue du Faubourg Saint Antoine, 75012 Paris, France. Email: catherine.beauvais@aphp.fr. Accepted for publication July 6, 2022.
Françoise Fayet
The study was supported by an institutional grant from the University Hospital of Clermont-Ferrand (Centre Hospitalier Universitaire Gabriel-Montpied, Clermont-Ferrand, France; reference AOI RODERE 2016). C. Beauvais, MD, Service de Rhumatologie Centre Hospitalier Universitaire Saint Antoine, Sorbonne Université, AP-HP, Paris; 2. Pereira, PhD, Département de Biostatistique Centre Hospitalier Universitaire Gabriel-Montpied, Clermont-Ferrand; T. Pham, MD, PhD, Service de Rhumatologie, Centre Hospitalier Universitaire Sainte Marguerite, Université Aix Marseille, Marseille; C. Sordet, MD, PhD, Service de Rhumatologie, Hôpitaux Universitaires Strasbourg, Strasbourg; P. Claudepierre, MD, PhD, Service de Rhumatologie, Centre Hospitalier Universitaire Henri Mondor, AP-HP, Université Créteil, Paris; F. Fayet, BSc, M. Soubrier, MD, PhD, M. Rodère, BSc, Service de Rhumatologie, Centre Hospitalier Universitaire Gabriel-Montpied, Clermont-Ferrand; D. Wendling, MD, PhD, Service de Rhumatologie, Centre Hospitalier Régional Universitaire de Besançon, and EA 4266 EPILAB, Université Bourgogne Franche-Comté, Besançon; F. Costantino, MD, PhD, Service de Rhumatologie, Hôpital Universitaire Ambroise Paré, AP-HP, Université Paris Saclay, Boulogne-Billancourt; L. Carton, Association AFLAR (Association Française de Lutte Anti-Rhumatismale), Paris; L. Grange, MD, PhD, Service de Rhumatologie, Centre Hospitalier Universitaire Grenoble Alpes, Echirolles; N. Legoupil, MD, Service de Rhumatologie, Centre Hospitalier Universitaire Cochin, AP-HP, Paris; A. Perdriger, MD, PhD, Service de Rhumatologie, Centre Hospitalier Universitaire, Rennes; I. Tavares, Service de Rééducation, Hôpital Universitaire Montpellier, Montpellier; E. Dernis, MD, MSc, Service de Rhumatologie, Hôpital Le Mans, Le Mans; L. Gossec, Sorbonne Université, Institut Pierre Louis d'Epidémiologie et de Santé Publique, INSERM, and Service de Rhumatologie, Centre Hospitalier Universitaire Pitié Salpétrière, Sorbonne Université AP-HP, Paris France. CB has received research grants from BMS, Fresenius Kabi, Eli Lilly, and Mylan; advisory board fees from Novartis and Sandoz; and speaker fees from BMS, AbbVie, MSD, Mylan, Pfizer, Roche, Sanofi, and UCB. TP has received speaker and consulting fees from AbbVie, Amgen, Biogen, BMS, Celgene, Fresenius Kabi, Janssen, Eli Lilly, MSD, Nordic Pharma, Novartis, Pfizer, Sandoz, Sanofi, and UCB. CS has received consulting fees from AbbVie, UCB, Eli Lilly, Nordic Pharma, GSK, Roche Chugaï, and BMS. DW has received speaker fees from AbbVie, BMS, MSD, Pfizer, Chugaï, Nordic Pharma, UCB, Novartis, Eli Lilly, Amgen, Grunenthal, and Galapagos; advisory board fees from Novartis, Janssen, AbbVie, and Amgen; and support for attending meetings from MSD, Galapagos, Chugaï, UCB, Mylan, and Fresenius Kabi. FC has received consulting and/or speaker fees from Eli Lilly, Novartis, and UCB. LG has received research grants from Amgen, Galapagos, Janssen, Eli Lilly, Pfizer, Sandoz, Sanofi; and consulting fees from AbbVie, Amgen, BMS, Biogen, Celgene, Galapagos, Gilead, Janssen, Eli Lilly, Novartis, Pfizer, Samsung Bioepis, Sanofi-Aventis, and UCB. The remaining authors declare no conflicts of interest. Address correspondence to Dr. C. Beauvais, Service de Rhumatologie Centre Hospitalier Universitaire Saint Antoine, Sorbonne Université, AP-HP, 184 rue du Faubourg Saint Antoine, 75012 Paris, France. Email: catherine.beauvais@aphp.fr. Accepted for publication July 6, 2022.
Daniel Wendling
The study was supported by an institutional grant from the University Hospital of Clermont-Ferrand (Centre Hospitalier Universitaire Gabriel-Montpied, Clermont-Ferrand, France; reference AOI RODERE 2016). C. Beauvais, MD, Service de Rhumatologie Centre Hospitalier Universitaire Saint Antoine, Sorbonne Université, AP-HP, Paris; 2. Pereira, PhD, Département de Biostatistique Centre Hospitalier Universitaire Gabriel-Montpied, Clermont-Ferrand; T. Pham, MD, PhD, Service de Rhumatologie, Centre Hospitalier Universitaire Sainte Marguerite, Université Aix Marseille, Marseille; C. Sordet, MD, PhD, Service de Rhumatologie, Hôpitaux Universitaires Strasbourg, Strasbourg; P. Claudepierre, MD, PhD, Service de Rhumatologie, Centre Hospitalier Universitaire Henri Mondor, AP-HP, Université Créteil, Paris; F. Fayet, BSc, M. Soubrier, MD, PhD, M. Rodère, BSc, Service de Rhumatologie, Centre Hospitalier Universitaire Gabriel-Montpied, Clermont-Ferrand; D. Wendling, MD, PhD, Service de Rhumatologie, Centre Hospitalier Régional Universitaire de Besançon, and EA 4266 EPILAB, Université Bourgogne Franche-Comté, Besançon; F. Costantino, MD, PhD, Service de Rhumatologie, Hôpital Universitaire Ambroise Paré, AP-HP, Université Paris Saclay, Boulogne-Billancourt; L. Carton, Association AFLAR (Association Française de Lutte Anti-Rhumatismale), Paris; L. Grange, MD, PhD, Service de Rhumatologie, Centre Hospitalier Universitaire Grenoble Alpes, Echirolles; N. Legoupil, MD, Service de Rhumatologie, Centre Hospitalier Universitaire Cochin, AP-HP, Paris; A. Perdriger, MD, PhD, Service de Rhumatologie, Centre Hospitalier Universitaire, Rennes; I. Tavares, Service de Rééducation, Hôpital Universitaire Montpellier, Montpellier; E. Dernis, MD, MSc, Service de Rhumatologie, Hôpital Le Mans, Le Mans; L. Gossec, Sorbonne Université, Institut Pierre Louis d'Epidémiologie et de Santé Publique, INSERM, and Service de Rhumatologie, Centre Hospitalier Universitaire Pitié Salpétrière, Sorbonne Université AP-HP, Paris France. CB has received research grants from BMS, Fresenius Kabi, Eli Lilly, and Mylan; advisory board fees from Novartis and Sandoz; and speaker fees from BMS, AbbVie, MSD, Mylan, Pfizer, Roche, Sanofi, and UCB. TP has received speaker and consulting fees from AbbVie, Amgen, Biogen, BMS, Celgene, Fresenius Kabi, Janssen, Eli Lilly, MSD, Nordic Pharma, Novartis, Pfizer, Sandoz, Sanofi, and UCB. CS has received consulting fees from AbbVie, UCB, Eli Lilly, Nordic Pharma, GSK, Roche Chugaï, and BMS. DW has received speaker fees from AbbVie, BMS, MSD, Pfizer, Chugaï, Nordic Pharma, UCB, Novartis, Eli Lilly, Amgen, Grunenthal, and Galapagos; advisory board fees from Novartis, Janssen, AbbVie, and Amgen; and support for attending meetings from MSD, Galapagos, Chugaï, UCB, Mylan, and Fresenius Kabi. FC has received consulting and/or speaker fees from Eli Lilly, Novartis, and UCB. LG has received research grants from Amgen, Galapagos, Janssen, Eli Lilly, Pfizer, Sandoz, Sanofi; and consulting fees from AbbVie, Amgen, BMS, Biogen, Celgene, Galapagos, Gilead, Janssen, Eli Lilly, Novartis, Pfizer, Samsung Bioepis, Sanofi-Aventis, and UCB. The remaining authors declare no conflicts of interest. Address correspondence to Dr. C. Beauvais, Service de Rhumatologie Centre Hospitalier Universitaire Saint Antoine, Sorbonne Université, AP-HP, 184 rue du Faubourg Saint Antoine, 75012 Paris, France. Email: catherine.beauvais@aphp.fr. Accepted for publication July 6, 2022.
Félicie Costantino
The study was supported by an institutional grant from the University Hospital of Clermont-Ferrand (Centre Hospitalier Universitaire Gabriel-Montpied, Clermont-Ferrand, France; reference AOI RODERE 2016). C. Beauvais, MD, Service de Rhumatologie Centre Hospitalier Universitaire Saint Antoine, Sorbonne Université, AP-HP, Paris; 2. Pereira, PhD, Département de Biostatistique Centre Hospitalier Universitaire Gabriel-Montpied, Clermont-Ferrand; T. Pham, MD, PhD, Service de Rhumatologie, Centre Hospitalier Universitaire Sainte Marguerite, Université Aix Marseille, Marseille; C. Sordet, MD, PhD, Service de Rhumatologie, Hôpitaux Universitaires Strasbourg, Strasbourg; P. Claudepierre, MD, PhD, Service de Rhumatologie, Centre Hospitalier Universitaire Henri Mondor, AP-HP, Université Créteil, Paris; F. Fayet, BSc, M. Soubrier, MD, PhD, M. Rodère, BSc, Service de Rhumatologie, Centre Hospitalier Universitaire Gabriel-Montpied, Clermont-Ferrand; D. Wendling, MD, PhD, Service de Rhumatologie, Centre Hospitalier Régional Universitaire de Besançon, and EA 4266 EPILAB, Université Bourgogne Franche-Comté, Besançon; F. Costantino, MD, PhD, Service de Rhumatologie, Hôpital Universitaire Ambroise Paré, AP-HP, Université Paris Saclay, Boulogne-Billancourt; L. Carton, Association AFLAR (Association Française de Lutte Anti-Rhumatismale), Paris; L. Grange, MD, PhD, Service de Rhumatologie, Centre Hospitalier Universitaire Grenoble Alpes, Echirolles; N. Legoupil, MD, Service de Rhumatologie, Centre Hospitalier Universitaire Cochin, AP-HP, Paris; A. Perdriger, MD, PhD, Service de Rhumatologie, Centre Hospitalier Universitaire, Rennes; I. Tavares, Service de Rééducation, Hôpital Universitaire Montpellier, Montpellier; E. Dernis, MD, MSc, Service de Rhumatologie, Hôpital Le Mans, Le Mans; L. Gossec, Sorbonne Université, Institut Pierre Louis d'Epidémiologie et de Santé Publique, INSERM, and Service de Rhumatologie, Centre Hospitalier Universitaire Pitié Salpétrière, Sorbonne Université AP-HP, Paris France. CB has received research grants from BMS, Fresenius Kabi, Eli Lilly, and Mylan; advisory board fees from Novartis and Sandoz; and speaker fees from BMS, AbbVie, MSD, Mylan, Pfizer, Roche, Sanofi, and UCB. TP has received speaker and consulting fees from AbbVie, Amgen, Biogen, BMS, Celgene, Fresenius Kabi, Janssen, Eli Lilly, MSD, Nordic Pharma, Novartis, Pfizer, Sandoz, Sanofi, and UCB. CS has received consulting fees from AbbVie, UCB, Eli Lilly, Nordic Pharma, GSK, Roche Chugaï, and BMS. DW has received speaker fees from AbbVie, BMS, MSD, Pfizer, Chugaï, Nordic Pharma, UCB, Novartis, Eli Lilly, Amgen, Grunenthal, and Galapagos; advisory board fees from Novartis, Janssen, AbbVie, and Amgen; and support for attending meetings from MSD, Galapagos, Chugaï, UCB, Mylan, and Fresenius Kabi. FC has received consulting and/or speaker fees from Eli Lilly, Novartis, and UCB. LG has received research grants from Amgen, Galapagos, Janssen, Eli Lilly, Pfizer, Sandoz, Sanofi; and consulting fees from AbbVie, Amgen, BMS, Biogen, Celgene, Galapagos, Gilead, Janssen, Eli Lilly, Novartis, Pfizer, Samsung Bioepis, Sanofi-Aventis, and UCB. The remaining authors declare no conflicts of interest. Address correspondence to Dr. C. Beauvais, Service de Rhumatologie Centre Hospitalier Universitaire Saint Antoine, Sorbonne Université, AP-HP, 184 rue du Faubourg Saint Antoine, 75012 Paris, France. Email: catherine.beauvais@aphp.fr. Accepted for publication July 6, 2022.
Laurence Carton
The study was supported by an institutional grant from the University Hospital of Clermont-Ferrand (Centre Hospitalier Universitaire Gabriel-Montpied, Clermont-Ferrand, France; reference AOI RODERE 2016). C. Beauvais, MD, Service de Rhumatologie Centre Hospitalier Universitaire Saint Antoine, Sorbonne Université, AP-HP, Paris; 2. Pereira, PhD, Département de Biostatistique Centre Hospitalier Universitaire Gabriel-Montpied, Clermont-Ferrand; T. Pham, MD, PhD, Service de Rhumatologie, Centre Hospitalier Universitaire Sainte Marguerite, Université Aix Marseille, Marseille; C. Sordet, MD, PhD, Service de Rhumatologie, Hôpitaux Universitaires Strasbourg, Strasbourg; P. Claudepierre, MD, PhD, Service de Rhumatologie, Centre Hospitalier Universitaire Henri Mondor, AP-HP, Université Créteil, Paris; F. Fayet, BSc, M. Soubrier, MD, PhD, M. Rodère, BSc, Service de Rhumatologie, Centre Hospitalier Universitaire Gabriel-Montpied, Clermont-Ferrand; D. Wendling, MD, PhD, Service de Rhumatologie, Centre Hospitalier Régional Universitaire de Besançon, and EA 4266 EPILAB, Université Bourgogne Franche-Comté, Besançon; F. Costantino, MD, PhD, Service de Rhumatologie, Hôpital Universitaire Ambroise Paré, AP-HP, Université Paris Saclay, Boulogne-Billancourt; L. Carton, Association AFLAR (Association Française de Lutte Anti-Rhumatismale), Paris; L. Grange, MD, PhD, Service de Rhumatologie, Centre Hospitalier Universitaire Grenoble Alpes, Echirolles; N. Legoupil, MD, Service de Rhumatologie, Centre Hospitalier Universitaire Cochin, AP-HP, Paris; A. Perdriger, MD, PhD, Service de Rhumatologie, Centre Hospitalier Universitaire, Rennes; I. Tavares, Service de Rééducation, Hôpital Universitaire Montpellier, Montpellier; E. Dernis, MD, MSc, Service de Rhumatologie, Hôpital Le Mans, Le Mans; L. Gossec, Sorbonne Université, Institut Pierre Louis d'Epidémiologie et de Santé Publique, INSERM, and Service de Rhumatologie, Centre Hospitalier Universitaire Pitié Salpétrière, Sorbonne Université AP-HP, Paris France. CB has received research grants from BMS, Fresenius Kabi, Eli Lilly, and Mylan; advisory board fees from Novartis and Sandoz; and speaker fees from BMS, AbbVie, MSD, Mylan, Pfizer, Roche, Sanofi, and UCB. TP has received speaker and consulting fees from AbbVie, Amgen, Biogen, BMS, Celgene, Fresenius Kabi, Janssen, Eli Lilly, MSD, Nordic Pharma, Novartis, Pfizer, Sandoz, Sanofi, and UCB. CS has received consulting fees from AbbVie, UCB, Eli Lilly, Nordic Pharma, GSK, Roche Chugaï, and BMS. DW has received speaker fees from AbbVie, BMS, MSD, Pfizer, Chugaï, Nordic Pharma, UCB, Novartis, Eli Lilly, Amgen, Grunenthal, and Galapagos; advisory board fees from Novartis, Janssen, AbbVie, and Amgen; and support for attending meetings from MSD, Galapagos, Chugaï, UCB, Mylan, and Fresenius Kabi. FC has received consulting and/or speaker fees from Eli Lilly, Novartis, and UCB. LG has received research grants from Amgen, Galapagos, Janssen, Eli Lilly, Pfizer, Sandoz, Sanofi; and consulting fees from AbbVie, Amgen, BMS, Biogen, Celgene, Galapagos, Gilead, Janssen, Eli Lilly, Novartis, Pfizer, Samsung Bioepis, Sanofi-Aventis, and UCB. The remaining authors declare no conflicts of interest. Address correspondence to Dr. C. Beauvais, Service de Rhumatologie Centre Hospitalier Universitaire Saint Antoine, Sorbonne Université, AP-HP, 184 rue du Faubourg Saint Antoine, 75012 Paris, France. Email: catherine.beauvais@aphp.fr. Accepted for publication July 6, 2022.
Laurent Grange
The study was supported by an institutional grant from the University Hospital of Clermont-Ferrand (Centre Hospitalier Universitaire Gabriel-Montpied, Clermont-Ferrand, France; reference AOI RODERE 2016). C. Beauvais, MD, Service de Rhumatologie Centre Hospitalier Universitaire Saint Antoine, Sorbonne Université, AP-HP, Paris; 2. Pereira, PhD, Département de Biostatistique Centre Hospitalier Universitaire Gabriel-Montpied, Clermont-Ferrand; T. Pham, MD, PhD, Service de Rhumatologie, Centre Hospitalier Universitaire Sainte Marguerite, Université Aix Marseille, Marseille; C. Sordet, MD, PhD, Service de Rhumatologie, Hôpitaux Universitaires Strasbourg, Strasbourg; P. Claudepierre, MD, PhD, Service de Rhumatologie, Centre Hospitalier Universitaire Henri Mondor, AP-HP, Université Créteil, Paris; F. Fayet, BSc, M. Soubrier, MD, PhD, M. Rodère, BSc, Service de Rhumatologie, Centre Hospitalier Universitaire Gabriel-Montpied, Clermont-Ferrand; D. Wendling, MD, PhD, Service de Rhumatologie, Centre Hospitalier Régional Universitaire de Besançon, and EA 4266 EPILAB, Université Bourgogne Franche-Comté, Besançon; F. Costantino, MD, PhD, Service de Rhumatologie, Hôpital Universitaire Ambroise Paré, AP-HP, Université Paris Saclay, Boulogne-Billancourt; L. Carton, Association AFLAR (Association Française de Lutte Anti-Rhumatismale), Paris; L. Grange, MD, PhD, Service de Rhumatologie, Centre Hospitalier Universitaire Grenoble Alpes, Echirolles; N. Legoupil, MD, Service de Rhumatologie, Centre Hospitalier Universitaire Cochin, AP-HP, Paris; A. Perdriger, MD, PhD, Service de Rhumatologie, Centre Hospitalier Universitaire, Rennes; I. Tavares, Service de Rééducation, Hôpital Universitaire Montpellier, Montpellier; E. Dernis, MD, MSc, Service de Rhumatologie, Hôpital Le Mans, Le Mans; L. Gossec, Sorbonne Université, Institut Pierre Louis d'Epidémiologie et de Santé Publique, INSERM, and Service de Rhumatologie, Centre Hospitalier Universitaire Pitié Salpétrière, Sorbonne Université AP-HP, Paris France. CB has received research grants from BMS, Fresenius Kabi, Eli Lilly, and Mylan; advisory board fees from Novartis and Sandoz; and speaker fees from BMS, AbbVie, MSD, Mylan, Pfizer, Roche, Sanofi, and UCB. TP has received speaker and consulting fees from AbbVie, Amgen, Biogen, BMS, Celgene, Fresenius Kabi, Janssen, Eli Lilly, MSD, Nordic Pharma, Novartis, Pfizer, Sandoz, Sanofi, and UCB. CS has received consulting fees from AbbVie, UCB, Eli Lilly, Nordic Pharma, GSK, Roche Chugaï, and BMS. DW has received speaker fees from AbbVie, BMS, MSD, Pfizer, Chugaï, Nordic Pharma, UCB, Novartis, Eli Lilly, Amgen, Grunenthal, and Galapagos; advisory board fees from Novartis, Janssen, AbbVie, and Amgen; and support for attending meetings from MSD, Galapagos, Chugaï, UCB, Mylan, and Fresenius Kabi. FC has received consulting and/or speaker fees from Eli Lilly, Novartis, and UCB. LG has received research grants from Amgen, Galapagos, Janssen, Eli Lilly, Pfizer, Sandoz, Sanofi; and consulting fees from AbbVie, Amgen, BMS, Biogen, Celgene, Galapagos, Gilead, Janssen, Eli Lilly, Novartis, Pfizer, Samsung Bioepis, Sanofi-Aventis, and UCB. The remaining authors declare no conflicts of interest. Address correspondence to Dr. C. Beauvais, Service de Rhumatologie Centre Hospitalier Universitaire Saint Antoine, Sorbonne Université, AP-HP, 184 rue du Faubourg Saint Antoine, 75012 Paris, France. Email: catherine.beauvais@aphp.fr. Accepted for publication July 6, 2022.
Martin Soubrier
The study was supported by an institutional grant from the University Hospital of Clermont-Ferrand (Centre Hospitalier Universitaire Gabriel-Montpied, Clermont-Ferrand, France; reference AOI RODERE 2016). C. Beauvais, MD, Service de Rhumatologie Centre Hospitalier Universitaire Saint Antoine, Sorbonne Université, AP-HP, Paris; 2. Pereira, PhD, Département de Biostatistique Centre Hospitalier Universitaire Gabriel-Montpied, Clermont-Ferrand; T. Pham, MD, PhD, Service de Rhumatologie, Centre Hospitalier Universitaire Sainte Marguerite, Université Aix Marseille, Marseille; C. Sordet, MD, PhD, Service de Rhumatologie, Hôpitaux Universitaires Strasbourg, Strasbourg; P. Claudepierre, MD, PhD, Service de Rhumatologie, Centre Hospitalier Universitaire Henri Mondor, AP-HP, Université Créteil, Paris; F. Fayet, BSc, M. Soubrier, MD, PhD, M. Rodère, BSc, Service de Rhumatologie, Centre Hospitalier Universitaire Gabriel-Montpied, Clermont-Ferrand; D. Wendling, MD, PhD, Service de Rhumatologie, Centre Hospitalier Régional Universitaire de Besançon, and EA 4266 EPILAB, Université Bourgogne Franche-Comté, Besançon; F. Costantino, MD, PhD, Service de Rhumatologie, Hôpital Universitaire Ambroise Paré, AP-HP, Université Paris Saclay, Boulogne-Billancourt; L. Carton, Association AFLAR (Association Française de Lutte Anti-Rhumatismale), Paris; L. Grange, MD, PhD, Service de Rhumatologie, Centre Hospitalier Universitaire Grenoble Alpes, Echirolles; N. Legoupil, MD, Service de Rhumatologie, Centre Hospitalier Universitaire Cochin, AP-HP, Paris; A. Perdriger, MD, PhD, Service de Rhumatologie, Centre Hospitalier Universitaire, Rennes; I. Tavares, Service de Rééducation, Hôpital Universitaire Montpellier, Montpellier; E. Dernis, MD, MSc, Service de Rhumatologie, Hôpital Le Mans, Le Mans; L. Gossec, Sorbonne Université, Institut Pierre Louis d'Epidémiologie et de Santé Publique, INSERM, and Service de Rhumatologie, Centre Hospitalier Universitaire Pitié Salpétrière, Sorbonne Université AP-HP, Paris France. CB has received research grants from BMS, Fresenius Kabi, Eli Lilly, and Mylan; advisory board fees from Novartis and Sandoz; and speaker fees from BMS, AbbVie, MSD, Mylan, Pfizer, Roche, Sanofi, and UCB. TP has received speaker and consulting fees from AbbVie, Amgen, Biogen, BMS, Celgene, Fresenius Kabi, Janssen, Eli Lilly, MSD, Nordic Pharma, Novartis, Pfizer, Sandoz, Sanofi, and UCB. CS has received consulting fees from AbbVie, UCB, Eli Lilly, Nordic Pharma, GSK, Roche Chugaï, and BMS. DW has received speaker fees from AbbVie, BMS, MSD, Pfizer, Chugaï, Nordic Pharma, UCB, Novartis, Eli Lilly, Amgen, Grunenthal, and Galapagos; advisory board fees from Novartis, Janssen, AbbVie, and Amgen; and support for attending meetings from MSD, Galapagos, Chugaï, UCB, Mylan, and Fresenius Kabi. FC has received consulting and/or speaker fees from Eli Lilly, Novartis, and UCB. LG has received research grants from Amgen, Galapagos, Janssen, Eli Lilly, Pfizer, Sandoz, Sanofi; and consulting fees from AbbVie, Amgen, BMS, Biogen, Celgene, Galapagos, Gilead, Janssen, Eli Lilly, Novartis, Pfizer, Samsung Bioepis, Sanofi-Aventis, and UCB. The remaining authors declare no conflicts of interest. Address correspondence to Dr. C. Beauvais, Service de Rhumatologie Centre Hospitalier Universitaire Saint Antoine, Sorbonne Université, AP-HP, 184 rue du Faubourg Saint Antoine, 75012 Paris, France. Email: catherine.beauvais@aphp.fr. Accepted for publication July 6, 2022.
Nathalie Legoupil
The study was supported by an institutional grant from the University Hospital of Clermont-Ferrand (Centre Hospitalier Universitaire Gabriel-Montpied, Clermont-Ferrand, France; reference AOI RODERE 2016). C. Beauvais, MD, Service de Rhumatologie Centre Hospitalier Universitaire Saint Antoine, Sorbonne Université, AP-HP, Paris; 2. Pereira, PhD, Département de Biostatistique Centre Hospitalier Universitaire Gabriel-Montpied, Clermont-Ferrand; T. Pham, MD, PhD, Service de Rhumatologie, Centre Hospitalier Universitaire Sainte Marguerite, Université Aix Marseille, Marseille; C. Sordet, MD, PhD, Service de Rhumatologie, Hôpitaux Universitaires Strasbourg, Strasbourg; P. Claudepierre, MD, PhD, Service de Rhumatologie, Centre Hospitalier Universitaire Henri Mondor, AP-HP, Université Créteil, Paris; F. Fayet, BSc, M. Soubrier, MD, PhD, M. Rodère, BSc, Service de Rhumatologie, Centre Hospitalier Universitaire Gabriel-Montpied, Clermont-Ferrand; D. Wendling, MD, PhD, Service de Rhumatologie, Centre Hospitalier Régional Universitaire de Besançon, and EA 4266 EPILAB, Université Bourgogne Franche-Comté, Besançon; F. Costantino, MD, PhD, Service de Rhumatologie, Hôpital Universitaire Ambroise Paré, AP-HP, Université Paris Saclay, Boulogne-Billancourt; L. Carton, Association AFLAR (Association Française de Lutte Anti-Rhumatismale), Paris; L. Grange, MD, PhD, Service de Rhumatologie, Centre Hospitalier Universitaire Grenoble Alpes, Echirolles; N. Legoupil, MD, Service de Rhumatologie, Centre Hospitalier Universitaire Cochin, AP-HP, Paris; A. Perdriger, MD, PhD, Service de Rhumatologie, Centre Hospitalier Universitaire, Rennes; I. Tavares, Service de Rééducation, Hôpital Universitaire Montpellier, Montpellier; E. Dernis, MD, MSc, Service de Rhumatologie, Hôpital Le Mans, Le Mans; L. Gossec, Sorbonne Université, Institut Pierre Louis d'Epidémiologie et de Santé Publique, INSERM, and Service de Rhumatologie, Centre Hospitalier Universitaire Pitié Salpétrière, Sorbonne Université AP-HP, Paris France. CB has received research grants from BMS, Fresenius Kabi, Eli Lilly, and Mylan; advisory board fees from Novartis and Sandoz; and speaker fees from BMS, AbbVie, MSD, Mylan, Pfizer, Roche, Sanofi, and UCB. TP has received speaker and consulting fees from AbbVie, Amgen, Biogen, BMS, Celgene, Fresenius Kabi, Janssen, Eli Lilly, MSD, Nordic Pharma, Novartis, Pfizer, Sandoz, Sanofi, and UCB. CS has received consulting fees from AbbVie, UCB, Eli Lilly, Nordic Pharma, GSK, Roche Chugaï, and BMS. DW has received speaker fees from AbbVie, BMS, MSD, Pfizer, Chugaï, Nordic Pharma, UCB, Novartis, Eli Lilly, Amgen, Grunenthal, and Galapagos; advisory board fees from Novartis, Janssen, AbbVie, and Amgen; and support for attending meetings from MSD, Galapagos, Chugaï, UCB, Mylan, and Fresenius Kabi. FC has received consulting and/or speaker fees from Eli Lilly, Novartis, and UCB. LG has received research grants from Amgen, Galapagos, Janssen, Eli Lilly, Pfizer, Sandoz, Sanofi; and consulting fees from AbbVie, Amgen, BMS, Biogen, Celgene, Galapagos, Gilead, Janssen, Eli Lilly, Novartis, Pfizer, Samsung Bioepis, Sanofi-Aventis, and UCB. The remaining authors declare no conflicts of interest. Address correspondence to Dr. C. Beauvais, Service de Rhumatologie Centre Hospitalier Universitaire Saint Antoine, Sorbonne Université, AP-HP, 184 rue du Faubourg Saint Antoine, 75012 Paris, France. Email: catherine.beauvais@aphp.fr. Accepted for publication July 6, 2022.
Aleth Perdriger
The study was supported by an institutional grant from the University Hospital of Clermont-Ferrand (Centre Hospitalier Universitaire Gabriel-Montpied, Clermont-Ferrand, France; reference AOI RODERE 2016). C. Beauvais, MD, Service de Rhumatologie Centre Hospitalier Universitaire Saint Antoine, Sorbonne Université, AP-HP, Paris; 2. Pereira, PhD, Département de Biostatistique Centre Hospitalier Universitaire Gabriel-Montpied, Clermont-Ferrand; T. Pham, MD, PhD, Service de Rhumatologie, Centre Hospitalier Universitaire Sainte Marguerite, Université Aix Marseille, Marseille; C. Sordet, MD, PhD, Service de Rhumatologie, Hôpitaux Universitaires Strasbourg, Strasbourg; P. Claudepierre, MD, PhD, Service de Rhumatologie, Centre Hospitalier Universitaire Henri Mondor, AP-HP, Université Créteil, Paris; F. Fayet, BSc, M. Soubrier, MD, PhD, M. Rodère, BSc, Service de Rhumatologie, Centre Hospitalier Universitaire Gabriel-Montpied, Clermont-Ferrand; D. Wendling, MD, PhD, Service de Rhumatologie, Centre Hospitalier Régional Universitaire de Besançon, and EA 4266 EPILAB, Université Bourgogne Franche-Comté, Besançon; F. Costantino, MD, PhD, Service de Rhumatologie, Hôpital Universitaire Ambroise Paré, AP-HP, Université Paris Saclay, Boulogne-Billancourt; L. Carton, Association AFLAR (Association Française de Lutte Anti-Rhumatismale), Paris; L. Grange, MD, PhD, Service de Rhumatologie, Centre Hospitalier Universitaire Grenoble Alpes, Echirolles; N. Legoupil, MD, Service de Rhumatologie, Centre Hospitalier Universitaire Cochin, AP-HP, Paris; A. Perdriger, MD, PhD, Service de Rhumatologie, Centre Hospitalier Universitaire, Rennes; I. Tavares, Service de Rééducation, Hôpital Universitaire Montpellier, Montpellier; E. Dernis, MD, MSc, Service de Rhumatologie, Hôpital Le Mans, Le Mans; L. Gossec, Sorbonne Université, Institut Pierre Louis d'Epidémiologie et de Santé Publique, INSERM, and Service de Rhumatologie, Centre Hospitalier Universitaire Pitié Salpétrière, Sorbonne Université AP-HP, Paris France. CB has received research grants from BMS, Fresenius Kabi, Eli Lilly, and Mylan; advisory board fees from Novartis and Sandoz; and speaker fees from BMS, AbbVie, MSD, Mylan, Pfizer, Roche, Sanofi, and UCB. TP has received speaker and consulting fees from AbbVie, Amgen, Biogen, BMS, Celgene, Fresenius Kabi, Janssen, Eli Lilly, MSD, Nordic Pharma, Novartis, Pfizer, Sandoz, Sanofi, and UCB. CS has received consulting fees from AbbVie, UCB, Eli Lilly, Nordic Pharma, GSK, Roche Chugaï, and BMS. DW has received speaker fees from AbbVie, BMS, MSD, Pfizer, Chugaï, Nordic Pharma, UCB, Novartis, Eli Lilly, Amgen, Grunenthal, and Galapagos; advisory board fees from Novartis, Janssen, AbbVie, and Amgen; and support for attending meetings from MSD, Galapagos, Chugaï, UCB, Mylan, and Fresenius Kabi. FC has received consulting and/or speaker fees from Eli Lilly, Novartis, and UCB. LG has received research grants from Amgen, Galapagos, Janssen, Eli Lilly, Pfizer, Sandoz, Sanofi; and consulting fees from AbbVie, Amgen, BMS, Biogen, Celgene, Galapagos, Gilead, Janssen, Eli Lilly, Novartis, Pfizer, Samsung Bioepis, Sanofi-Aventis, and UCB. The remaining authors declare no conflicts of interest. Address correspondence to Dr. C. Beauvais, Service de Rhumatologie Centre Hospitalier Universitaire Saint Antoine, Sorbonne Université, AP-HP, 184 rue du Faubourg Saint Antoine, 75012 Paris, France. Email: catherine.beauvais@aphp.fr. Accepted for publication July 6, 2022.
Isabel Tavares
The study was supported by an institutional grant from the University Hospital of Clermont-Ferrand (Centre Hospitalier Universitaire Gabriel-Montpied, Clermont-Ferrand, France; reference AOI RODERE 2016). C. Beauvais, MD, Service de Rhumatologie Centre Hospitalier Universitaire Saint Antoine, Sorbonne Université, AP-HP, Paris; 2. Pereira, PhD, Département de Biostatistique Centre Hospitalier Universitaire Gabriel-Montpied, Clermont-Ferrand; T. Pham, MD, PhD, Service de Rhumatologie, Centre Hospitalier Universitaire Sainte Marguerite, Université Aix Marseille, Marseille; C. Sordet, MD, PhD, Service de Rhumatologie, Hôpitaux Universitaires Strasbourg, Strasbourg; P. Claudepierre, MD, PhD, Service de Rhumatologie, Centre Hospitalier Universitaire Henri Mondor, AP-HP, Université Créteil, Paris; F. Fayet, BSc, M. Soubrier, MD, PhD, M. Rodère, BSc, Service de Rhumatologie, Centre Hospitalier Universitaire Gabriel-Montpied, Clermont-Ferrand; D. Wendling, MD, PhD, Service de Rhumatologie, Centre Hospitalier Régional Universitaire de Besançon, and EA 4266 EPILAB, Université Bourgogne Franche-Comté, Besançon; F. Costantino, MD, PhD, Service de Rhumatologie, Hôpital Universitaire Ambroise Paré, AP-HP, Université Paris Saclay, Boulogne-Billancourt; L. Carton, Association AFLAR (Association Française de Lutte Anti-Rhumatismale), Paris; L. Grange, MD, PhD, Service de Rhumatologie, Centre Hospitalier Universitaire Grenoble Alpes, Echirolles; N. Legoupil, MD, Service de Rhumatologie, Centre Hospitalier Universitaire Cochin, AP-HP, Paris; A. Perdriger, MD, PhD, Service de Rhumatologie, Centre Hospitalier Universitaire, Rennes; I. Tavares, Service de Rééducation, Hôpital Universitaire Montpellier, Montpellier; E. Dernis, MD, MSc, Service de Rhumatologie, Hôpital Le Mans, Le Mans; L. Gossec, Sorbonne Université, Institut Pierre Louis d'Epidémiologie et de Santé Publique, INSERM, and Service de Rhumatologie, Centre Hospitalier Universitaire Pitié Salpétrière, Sorbonne Université AP-HP, Paris France. CB has received research grants from BMS, Fresenius Kabi, Eli Lilly, and Mylan; advisory board fees from Novartis and Sandoz; and speaker fees from BMS, AbbVie, MSD, Mylan, Pfizer, Roche, Sanofi, and UCB. TP has received speaker and consulting fees from AbbVie, Amgen, Biogen, BMS, Celgene, Fresenius Kabi, Janssen, Eli Lilly, MSD, Nordic Pharma, Novartis, Pfizer, Sandoz, Sanofi, and UCB. CS has received consulting fees from AbbVie, UCB, Eli Lilly, Nordic Pharma, GSK, Roche Chugaï, and BMS. DW has received speaker fees from AbbVie, BMS, MSD, Pfizer, Chugaï, Nordic Pharma, UCB, Novartis, Eli Lilly, Amgen, Grunenthal, and Galapagos; advisory board fees from Novartis, Janssen, AbbVie, and Amgen; and support for attending meetings from MSD, Galapagos, Chugaï, UCB, Mylan, and Fresenius Kabi. FC has received consulting and/or speaker fees from Eli Lilly, Novartis, and UCB. LG has received research grants from Amgen, Galapagos, Janssen, Eli Lilly, Pfizer, Sandoz, Sanofi; and consulting fees from AbbVie, Amgen, BMS, Biogen, Celgene, Galapagos, Gilead, Janssen, Eli Lilly, Novartis, Pfizer, Samsung Bioepis, Sanofi-Aventis, and UCB. The remaining authors declare no conflicts of interest. Address correspondence to Dr. C. Beauvais, Service de Rhumatologie Centre Hospitalier Universitaire Saint Antoine, Sorbonne Université, AP-HP, 184 rue du Faubourg Saint Antoine, 75012 Paris, France. Email: catherine.beauvais@aphp.fr. Accepted for publication July 6, 2022.
Emmanuelle Dernis
The study was supported by an institutional grant from the University Hospital of Clermont-Ferrand (Centre Hospitalier Universitaire Gabriel-Montpied, Clermont-Ferrand, France; reference AOI RODERE 2016). C. Beauvais, MD, Service de Rhumatologie Centre Hospitalier Universitaire Saint Antoine, Sorbonne Université, AP-HP, Paris; 2. Pereira, PhD, Département de Biostatistique Centre Hospitalier Universitaire Gabriel-Montpied, Clermont-Ferrand; T. Pham, MD, PhD, Service de Rhumatologie, Centre Hospitalier Universitaire Sainte Marguerite, Université Aix Marseille, Marseille; C. Sordet, MD, PhD, Service de Rhumatologie, Hôpitaux Universitaires Strasbourg, Strasbourg; P. Claudepierre, MD, PhD, Service de Rhumatologie, Centre Hospitalier Universitaire Henri Mondor, AP-HP, Université Créteil, Paris; F. Fayet, BSc, M. Soubrier, MD, PhD, M. Rodère, BSc, Service de Rhumatologie, Centre Hospitalier Universitaire Gabriel-Montpied, Clermont-Ferrand; D. Wendling, MD, PhD, Service de Rhumatologie, Centre Hospitalier Régional Universitaire de Besançon, and EA 4266 EPILAB, Université Bourgogne Franche-Comté, Besançon; F. Costantino, MD, PhD, Service de Rhumatologie, Hôpital Universitaire Ambroise Paré, AP-HP, Université Paris Saclay, Boulogne-Billancourt; L. Carton, Association AFLAR (Association Française de Lutte Anti-Rhumatismale), Paris; L. Grange, MD, PhD, Service de Rhumatologie, Centre Hospitalier Universitaire Grenoble Alpes, Echirolles; N. Legoupil, MD, Service de Rhumatologie, Centre Hospitalier Universitaire Cochin, AP-HP, Paris; A. Perdriger, MD, PhD, Service de Rhumatologie, Centre Hospitalier Universitaire, Rennes; I. Tavares, Service de Rééducation, Hôpital Universitaire Montpellier, Montpellier; E. Dernis, MD, MSc, Service de Rhumatologie, Hôpital Le Mans, Le Mans; L. Gossec, Sorbonne Université, Institut Pierre Louis d'Epidémiologie et de Santé Publique, INSERM, and Service de Rhumatologie, Centre Hospitalier Universitaire Pitié Salpétrière, Sorbonne Université AP-HP, Paris France. CB has received research grants from BMS, Fresenius Kabi, Eli Lilly, and Mylan; advisory board fees from Novartis and Sandoz; and speaker fees from BMS, AbbVie, MSD, Mylan, Pfizer, Roche, Sanofi, and UCB. TP has received speaker and consulting fees from AbbVie, Amgen, Biogen, BMS, Celgene, Fresenius Kabi, Janssen, Eli Lilly, MSD, Nordic Pharma, Novartis, Pfizer, Sandoz, Sanofi, and UCB. CS has received consulting fees from AbbVie, UCB, Eli Lilly, Nordic Pharma, GSK, Roche Chugaï, and BMS. DW has received speaker fees from AbbVie, BMS, MSD, Pfizer, Chugaï, Nordic Pharma, UCB, Novartis, Eli Lilly, Amgen, Grunenthal, and Galapagos; advisory board fees from Novartis, Janssen, AbbVie, and Amgen; and support for attending meetings from MSD, Galapagos, Chugaï, UCB, Mylan, and Fresenius Kabi. FC has received consulting and/or speaker fees from Eli Lilly, Novartis, and UCB. LG has received research grants from Amgen, Galapagos, Janssen, Eli Lilly, Pfizer, Sandoz, Sanofi; and consulting fees from AbbVie, Amgen, BMS, Biogen, Celgene, Galapagos, Gilead, Janssen, Eli Lilly, Novartis, Pfizer, Samsung Bioepis, Sanofi-Aventis, and UCB. The remaining authors declare no conflicts of interest. Address correspondence to Dr. C. Beauvais, Service de Rhumatologie Centre Hospitalier Universitaire Saint Antoine, Sorbonne Université, AP-HP, 184 rue du Faubourg Saint Antoine, 75012 Paris, France. Email: catherine.beauvais@aphp.fr. Accepted for publication July 6, 2022.
Laure Gossec
The study was supported by an institutional grant from the University Hospital of Clermont-Ferrand (Centre Hospitalier Universitaire Gabriel-Montpied, Clermont-Ferrand, France; reference AOI RODERE 2016). C. Beauvais, MD, Service de Rhumatologie Centre Hospitalier Universitaire Saint Antoine, Sorbonne Université, AP-HP, Paris; 2. Pereira, PhD, Département de Biostatistique Centre Hospitalier Universitaire Gabriel-Montpied, Clermont-Ferrand; T. Pham, MD, PhD, Service de Rhumatologie, Centre Hospitalier Universitaire Sainte Marguerite, Université Aix Marseille, Marseille; C. Sordet, MD, PhD, Service de Rhumatologie, Hôpitaux Universitaires Strasbourg, Strasbourg; P. Claudepierre, MD, PhD, Service de Rhumatologie, Centre Hospitalier Universitaire Henri Mondor, AP-HP, Université Créteil, Paris; F. Fayet, BSc, M. Soubrier, MD, PhD, M. Rodère, BSc, Service de Rhumatologie, Centre Hospitalier Universitaire Gabriel-Montpied, Clermont-Ferrand; D. Wendling, MD, PhD, Service de Rhumatologie, Centre Hospitalier Régional Universitaire de Besançon, and EA 4266 EPILAB, Université Bourgogne Franche-Comté, Besançon; F. Costantino, MD, PhD, Service de Rhumatologie, Hôpital Universitaire Ambroise Paré, AP-HP, Université Paris Saclay, Boulogne-Billancourt; L. Carton, Association AFLAR (Association Française de Lutte Anti-Rhumatismale), Paris; L. Grange, MD, PhD, Service de Rhumatologie, Centre Hospitalier Universitaire Grenoble Alpes, Echirolles; N. Legoupil, MD, Service de Rhumatologie, Centre Hospitalier Universitaire Cochin, AP-HP, Paris; A. Perdriger, MD, PhD, Service de Rhumatologie, Centre Hospitalier Universitaire, Rennes; I. Tavares, Service de Rééducation, Hôpital Universitaire Montpellier, Montpellier; E. Dernis, MD, MSc, Service de Rhumatologie, Hôpital Le Mans, Le Mans; L. Gossec, Sorbonne Université, Institut Pierre Louis d'Epidémiologie et de Santé Publique, INSERM, and Service de Rhumatologie, Centre Hospitalier Universitaire Pitié Salpétrière, Sorbonne Université AP-HP, Paris France. CB has received research grants from BMS, Fresenius Kabi, Eli Lilly, and Mylan; advisory board fees from Novartis and Sandoz; and speaker fees from BMS, AbbVie, MSD, Mylan, Pfizer, Roche, Sanofi, and UCB. TP has received speaker and consulting fees from AbbVie, Amgen, Biogen, BMS, Celgene, Fresenius Kabi, Janssen, Eli Lilly, MSD, Nordic Pharma, Novartis, Pfizer, Sandoz, Sanofi, and UCB. CS has received consulting fees from AbbVie, UCB, Eli Lilly, Nordic Pharma, GSK, Roche Chugaï, and BMS. DW has received speaker fees from AbbVie, BMS, MSD, Pfizer, Chugaï, Nordic Pharma, UCB, Novartis, Eli Lilly, Amgen, Grunenthal, and Galapagos; advisory board fees from Novartis, Janssen, AbbVie, and Amgen; and support for attending meetings from MSD, Galapagos, Chugaï, UCB, Mylan, and Fresenius Kabi. FC has received consulting and/or speaker fees from Eli Lilly, Novartis, and UCB. LG has received research grants from Amgen, Galapagos, Janssen, Eli Lilly, Pfizer, Sandoz, Sanofi; and consulting fees from AbbVie, Amgen, BMS, Biogen, Celgene, Galapagos, Gilead, Janssen, Eli Lilly, Novartis, Pfizer, Samsung Bioepis, Sanofi-Aventis, and UCB. The remaining authors declare no conflicts of interest. Address correspondence to Dr. C. Beauvais, Service de Rhumatologie Centre Hospitalier Universitaire Saint Antoine, Sorbonne Université, AP-HP, 184 rue du Faubourg Saint Antoine, 75012 Paris, France. Email: catherine.beauvais@aphp.fr. Accepted for publication July 6, 2022.
Malory Rodère
The study was supported by an institutional grant from the University Hospital of Clermont-Ferrand (Centre Hospitalier Universitaire Gabriel-Montpied, Clermont-Ferrand, France; reference AOI RODERE 2016). C. Beauvais, MD, Service de Rhumatologie Centre Hospitalier Universitaire Saint Antoine, Sorbonne Université, AP-HP, Paris; 2. Pereira, PhD, Département de Biostatistique Centre Hospitalier Universitaire Gabriel-Montpied, Clermont-Ferrand; T. Pham, MD, PhD, Service de Rhumatologie, Centre Hospitalier Universitaire Sainte Marguerite, Université Aix Marseille, Marseille; C. Sordet, MD, PhD, Service de Rhumatologie, Hôpitaux Universitaires Strasbourg, Strasbourg; P. Claudepierre, MD, PhD, Service de Rhumatologie, Centre Hospitalier Universitaire Henri Mondor, AP-HP, Université Créteil, Paris; F. Fayet, BSc, M. Soubrier, MD, PhD, M. Rodère, BSc, Service de Rhumatologie, Centre Hospitalier Universitaire Gabriel-Montpied, Clermont-Ferrand; D. Wendling, MD, PhD, Service de Rhumatologie, Centre Hospitalier Régional Universitaire de Besançon, and EA 4266 EPILAB, Université Bourgogne Franche-Comté, Besançon; F. Costantino, MD, PhD, Service de Rhumatologie, Hôpital Universitaire Ambroise Paré, AP-HP, Université Paris Saclay, Boulogne-Billancourt; L. Carton, Association AFLAR (Association Française de Lutte Anti-Rhumatismale), Paris; L. Grange, MD, PhD, Service de Rhumatologie, Centre Hospitalier Universitaire Grenoble Alpes, Echirolles; N. Legoupil, MD, Service de Rhumatologie, Centre Hospitalier Universitaire Cochin, AP-HP, Paris; A. Perdriger, MD, PhD, Service de Rhumatologie, Centre Hospitalier Universitaire, Rennes; I. Tavares, Service de Rééducation, Hôpital Universitaire Montpellier, Montpellier; E. Dernis, MD, MSc, Service de Rhumatologie, Hôpital Le Mans, Le Mans; L. Gossec, Sorbonne Université, Institut Pierre Louis d'Epidémiologie et de Santé Publique, INSERM, and Service de Rhumatologie, Centre Hospitalier Universitaire Pitié Salpétrière, Sorbonne Université AP-HP, Paris France. CB has received research grants from BMS, Fresenius Kabi, Eli Lilly, and Mylan; advisory board fees from Novartis and Sandoz; and speaker fees from BMS, AbbVie, MSD, Mylan, Pfizer, Roche, Sanofi, and UCB. TP has received speaker and consulting fees from AbbVie, Amgen, Biogen, BMS, Celgene, Fresenius Kabi, Janssen, Eli Lilly, MSD, Nordic Pharma, Novartis, Pfizer, Sandoz, Sanofi, and UCB. CS has received consulting fees from AbbVie, UCB, Eli Lilly, Nordic Pharma, GSK, Roche Chugaï, and BMS. DW has received speaker fees from AbbVie, BMS, MSD, Pfizer, Chugaï, Nordic Pharma, UCB, Novartis, Eli Lilly, Amgen, Grunenthal, and Galapagos; advisory board fees from Novartis, Janssen, AbbVie, and Amgen; and support for attending meetings from MSD, Galapagos, Chugaï, UCB, Mylan, and Fresenius Kabi. FC has received consulting and/or speaker fees from Eli Lilly, Novartis, and UCB. LG has received research grants from Amgen, Galapagos, Janssen, Eli Lilly, Pfizer, Sandoz, Sanofi; and consulting fees from AbbVie, Amgen, BMS, Biogen, Celgene, Galapagos, Gilead, Janssen, Eli Lilly, Novartis, Pfizer, Samsung Bioepis, Sanofi-Aventis, and UCB. The remaining authors declare no conflicts of interest. Address correspondence to Dr. C. Beauvais, Service de Rhumatologie Centre Hospitalier Universitaire Saint Antoine, Sorbonne Université, AP-HP, 184 rue du Faubourg Saint Antoine, 75012 Paris, France. Email: catherine.beauvais@aphp.fr. Accepted for publication July 6, 2022.
Published eLetters
eLetters are comments published online only and are not peer-reviewed. Publication of eLetter submissions is not guaranteed, and all submissions are reviewed and edited at the discretion of The Journal's staff.
If you wish to publish Letters to the Editor or Correspondence, please submit through our online submission system ScholarOne Manuscripts.
Jump to comment:
No eLetters have been published for this article.
In this issue
The Journal of Rheumatology
Vol. 51, Issue 4
1 Apr 2024
Development and Validation of a Self-Administered Questionnaire Measuring Essential Knowledge in Patients With Axial Spondyloarthritis
Catherine Beauvais, Bruno Pereira, Thao Pham, Christelle Sordet, Pascal Claudepierre, Françoise Fayet, Daniel Wendling, Félicie Costantino, Laurence Carton, Laurent Grange, Martin Soubrier, Nathalie Legoupil, Aleth Perdriger, Isabel Tavares, Emmanuelle Dernis, Laure Gossec, Malory Rodère
The Journal of Rheumatology Jul 2022, jrheum.211314; DOI: 10.3899/jrheum.211314
Development and Validation of a Self-Administered Questionnaire Measuring Essential Knowledge in Patients With Axial Spondyloarthritis
Catherine Beauvais, Bruno Pereira, Thao Pham, Christelle Sordet, Pascal Claudepierre, Françoise Fayet, Daniel Wendling, Félicie Costantino, Laurence Carton, Laurent Grange, Martin Soubrier, Nathalie Legoupil, Aleth Perdriger, Isabel Tavares, Emmanuelle Dernis, Laure Gossec, Malory Rodère
The Journal of Rheumatology Jul 2022, jrheum.211314; DOI: 10.3899/jrheum.211314